ATE243198T1 - Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen - Google Patents

Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen

Info

Publication number
ATE243198T1
ATE243198T1 AT98901776T AT98901776T ATE243198T1 AT E243198 T1 ATE243198 T1 AT E243198T1 AT 98901776 T AT98901776 T AT 98901776T AT 98901776 T AT98901776 T AT 98901776T AT E243198 T1 ATE243198 T1 AT E243198T1
Authority
AT
Austria
Prior art keywords
compounds
pathogens
methods
claveable
inactivation
Prior art date
Application number
AT98901776T
Other languages
English (en)
Inventor
David Cook
John Merritt
Aileen Nerio
Henry Rapoport
Adonis Stassinopoulos
Susan Wollowitz
Jon Matejovic
William Denny
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Application granted granted Critical
Publication of ATE243198T1 publication Critical patent/ATE243198T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0209Multiple bag systems for separating or storing blood components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28033Membrane, sheet, cloth, pad, lamellar or mat
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/64Acridine or hydrogenated acridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
AT98901776T 1997-01-06 1998-01-06 Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen ATE243198T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77988597A 1997-01-06 1997-01-06
US77983097A 1997-01-07 1997-01-07
US4369697P 1997-04-15 1997-04-15
PCT/US1998/000532 WO1998030545A1 (en) 1997-01-06 1998-01-06 Frangible compounds for pathogen inactivation

Publications (1)

Publication Number Publication Date
ATE243198T1 true ATE243198T1 (de) 2003-07-15

Family

ID=27366374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901776T ATE243198T1 (de) 1997-01-06 1998-01-06 Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen

Country Status (9)

Country Link
EP (1) EP1021414B1 (de)
JP (2) JP4551502B2 (de)
CN (2) CN1248245B (de)
AT (1) ATE243198T1 (de)
AU (1) AU744089C (de)
CA (1) CA2276532C (de)
DE (1) DE69815703T2 (de)
ES (1) ES2196530T3 (de)
WO (1) WO1998030545A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030545A1 (en) * 1997-01-06 1998-07-16 Cerus Corporation Frangible compounds for pathogen inactivation
WO1999034839A1 (en) 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
JP2002517435A (ja) 1998-06-11 2002-06-18 シーラス コーポレイション 動脈平滑筋細胞の増殖阻害のためのアルキル化化合物の使用
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20020042043A1 (en) * 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
WO2003061379A2 (en) * 2000-12-21 2003-07-31 Cerus Corporation Methods for inactivation of pathogens in biological materials
MXPA05008342A (es) 2003-02-06 2006-02-28 Cerus Corp Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas.
CA2515298C (en) * 2003-02-06 2014-04-08 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
PL1838355T3 (pl) 2004-10-29 2014-01-31 Cerus Corp Ulepszone sposoby wygaszania dla procesu inaktywacji czerwonych krwinek
CN102046006B (zh) 2008-04-09 2014-09-24 塞鲁斯公司 用于红细胞病原体灭活的改进猝灭方法
EP2956138B1 (de) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutische verbindungen und verwendungen davon
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
CA3003097A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (de) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Kristalline formen therapeutischer verbindungen und verwendungen davon
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
WO2018119462A1 (en) 2016-12-23 2018-06-28 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
MX390725B (es) 2017-03-03 2025-03-21 Cerus Corp Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
AU2018395525B2 (en) 2017-12-29 2023-09-14 Cerus Corporation Systems and methods for treating biological fluids
BR112021025784A2 (pt) 2019-06-22 2022-03-03 Cerus Corp Sistemas de tratamento de fluido biológico
WO2020264421A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6402494A (en) * 1993-03-11 1994-09-26 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
AU722811B2 (en) * 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents
WO1998030545A1 (en) * 1997-01-06 1998-07-16 Cerus Corporation Frangible compounds for pathogen inactivation

Also Published As

Publication number Publication date
WO1998030545A1 (en) 1998-07-16
CA2276532C (en) 2008-06-17
CA2276532A1 (en) 1998-07-16
EP1021414A1 (de) 2000-07-26
CN1248245B (zh) 2012-07-04
ES2196530T3 (es) 2003-12-16
HK1026702A1 (en) 2000-12-22
JP5244083B2 (ja) 2013-07-24
AU744089B2 (en) 2002-02-14
CN101676268B (zh) 2013-09-25
DE69815703D1 (de) 2003-07-24
CN101676268A (zh) 2010-03-24
AU744089C (en) 2003-07-31
EP1021414B1 (de) 2003-06-18
DE69815703T2 (de) 2004-06-03
HK1188441A1 (en) 2014-05-02
CN1248245A (zh) 2000-03-22
JP4551502B2 (ja) 2010-09-29
JP2001508449A (ja) 2001-06-26
JP2010095527A (ja) 2010-04-30
AU5821798A (en) 1998-08-03

Similar Documents

Publication Publication Date Title
ATE243198T1 (de) Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen
ATE287210T1 (de) Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen
DE69328685D1 (de) Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen
DE69328777D1 (de) Dekontaminierung von Plättchen mit 8-Methoxypsoralen
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
AU9058091A (en) Preparation of nucleic acid samples
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60212964D1 (de) Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
DE69434445D1 (de) Verfahren zur sterilisation biologischer zusammensetzungen und das dabei erhaltene produkt
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
Blajchman Protecting the blood supply from emerging pathogens: the role of pathogen inactivation
ATE460947T1 (de) Verfahren zur sterilisation von biologischen präparaten
CN101757616A (zh) 一种安全的冻干哺乳动物源凝血酶制剂及其制备方法
DE60002172D1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv
DE59405845D1 (de) Verwendung von 2-Methylamino-2-phenylcyclohexanon zur Behandlung von Infektionen und zur Immunmodulation
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
ATE275984T1 (de) Biokompatible kolloide mit geringer zelladhäsion und aktiver stabilisierung von blutproteinen
UA23145A (uk) Спосіб визhачеhhя активhості бромелаїhу

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties